Before this thread dies away, this morning Esperion announced the positive Phase 3 top line data of another trial. This one is the bempedoic acid and ezetimibe combo pill. They also provided updated guidance in their press release of the timing of top-line data release for their last safery/tolerability/LDL-C lowering Study 2 (Phase 3, 52-week) revised to October from September.

One thing really holding back Resverlogix, in my opinion, is their ineffective communication about the status of BETonMACE. From the questions surrounding the timing and plan for the SSRA, to amendment(s) to the BETonMACE trial protocol that have not been formally announced or revised on ClinicalTrials.gov, to the timing of the expected BETonMACE top line data being early 2019 and not end of 2018, to the kicking of the Renal and Fabrys trials cans down the road, etc. Resverlogix is not doing themselves any favors with investors with these communication snafus. Because of this, we are seeing analyst reports and Seeking Alpha articles with incomplete stories and sometimes inaccurate information. I don't blame the analyst or writers. I blame Resverlogix. Esperion can be criticized for many things for sure. But one thing that can be said is that Esperion has stellar company/investor communications. Resverlogix could learn a thing or two from Esperion on this front. With all of the events on deck for Resverlogix, I sure hope they see this post and take this criticism to heart. 

BearDownAZ